Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20083457 | 0.92 | NR1I2 (0.50) | NR1I2SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL22857489 | 0.92 | NR1I2 (0.50) | NR1I2SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL19478566 | 0.91 | NR1I2 (0.49) | NR1I2SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL23169070 | 0.87 | SLC6A2 (0.46) | NR1I2SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL16668621 | 0.87 | NR1I2 (0.61) | NR1I2SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL9139072 | 0.87 | NR1I2 (0.61) | NR1I2SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL11861186 | 0.86 | NR1I2 (0.45) | NR1I2SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL24597837 | 0.84 | ESR1 (0.44) | NR1I2SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL24597751 | 0.84 | ESR1 (0.44) | NR1I2SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL19987462 | 0.84 | ESR1 (0.44) | NR1I2SLC6A2SLC6A4SLC6A3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | NR1I2 1266/4885SLC6A2 1080/4885SLC6A4 874/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | NR1I2 1266/4885SLC6A2 1080/4885SLC6A4 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.